Pergamon

Bioorganic & Medicinal Chemistry Letters 8 (1998) 567–568

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

SYNTHESIS AND IN VITRO CANCER CELL GROWTH INHIBITORY ACTIVITY OF MONOCYCLIC MODEL COMPOUNDS CONTAINING SPONGISTATIN TRIENE SIDE-CHAINS

Amos B. Smith, III* and Qiyan Lin

Department of Chemistry, Laboratory for Research on the Structure of Matter, and Monell Chemical Senses Center, University of Pennsylvania, Philadelphia, PA 19104, U.S.A.

George R. Pettit,* Jean-Charles Chapuis and Jean M. Schmidt

Cancer Research Institute and Department of Chemistry, Arizona State University, Box 871604, Tempe, AZ 85287, U.S.A.

Received 15 December 1997; accepted 19 January 1998

Abstract: Two monosaccharides embodying triene side-chains of the spongistatins display significant in vitro activity against human cancer cell lines.

The spongipyrans, a family of marine natural products with unique bisspiroketal architecture, are extraordinarily potent antitumor agents. The earliest example, spongistatin 4, was isolated in 1982 by Pettit and coworkers.[1a] In 1993, the Pettit,[1] Fusetani[2] and Kitagawa groups[3] independently described spongistatins 1-9, cinachyrolide A, and the altohyrtins A-C, respectively. Spongistatins 1 and 2 (**1** & **2**, Scheme 1), proved to be extremely potent against several highly chemo-resistant tumor types, with GI_{50}s of 1.48 and 8.51 x 10^{-10} M,[1c] respectively. Further studies demonstrated that **1** inhibits the glutamate-induced polymerization of tubulin (IC_{50} 3.6 μM). This Letter details the synthesis and preliminary biological evaluation of simple model compounds containing two of the three triene side-chains of the spongipyrans.

Scheme 1



In our unified approach to the spongistatins,[4] the labile C(48-51) conjugated diene moiety of the side-chain will be introduced at the end of the synthesis. We therefore carried out model studies designed to test this segment of the proposed route. Our initial targets were trienes **3a** and **3b** (Scheme 1), in which a D-glucosyl moiety mimics the F-ring pyran. We envisioned that **3a**, which embodies the unsubstituted diene of spongistatin 2 (**2**), would be generated by Horner-Emmons olefination of the C(48) aldehyde **4** with diisopropyl allylphosphonate (**7**). The chlorinated diene in **3b**, the model for spongistatin 1 (**1**), was expected to arise from the same aldehyde upon treatment with propargyltrimethylsilane (**8**) and $TiCl_4$, according to the method of Pornet.[5] Precursor **4** in turn would be prepared via coupling of known building blocks, iodide **5**[6] with sulfone **6**,[7] followed by Julia methylenation.[8] We have not yet modeled the analogous bromo diene found in altohyrtin B.

Sulfone (-)-**6** was obtained in three steps from commercially available (*R*)-(+)-glycidol [(+)-**9**; Scheme 2]. Protection as the *p*-methoxybenzyl (PMB) ether (NaH, Bu_4NI, PMBCl; 72% yield) and quantitative epoxide opening with the lithio derivative of methyl phenyl sulfone furnished (-)-**11**;[9] the absolute configuration was confirmed by Mosher analysis.[10] Silylation (TBSOTf, 2,6-lut,

Scheme 2



PII: S0960-894X(98)00050-X

CH_2Cl_2; 100%) completed the synthesis of (-)-**6**.

Coupling of model iodide (+)-**5**, available in five steps from methyl α-D-glucopyranoside,[6] with sulfone (-)-**6** provided **12a,b**[9] in 96% yield as an inconsequential mixture of C(45) epimers (Scheme 3). Introduction of the methylene moiety via the Julia protocol[8] then furnished (+)-**13**[9] (83%). The requisite aldehyde (+)-**4**[9] was generated by removal of the PMB ether with DDQ and Dess-Martin oxidation[11] of the resultant alcohol (83% yield, two steps). Olefination of (+)-**4** with **7** and desilylation furnished exclusively the desired E triene (+)-**3a**[9] (85% yield, two steps). Reaction of (+)-**4** with **8** and $TiCl_4$[5] followed by desilylation likewise afforded the desired E chloro analog (+)-**3b**[9] as a single isomer (49% yield, two steps).

Scheme 3



Preliminary screening has revealed that triene (+)-**3a** is active against six human cancer cell lines, and triene (+)-**3b** against five (Table 1). Surprisingly, the dechloro model compound **3a** displayed greater potency than **3b** in all assays. A variety of other spongistatin analogs are currently under investigation.

Table 1. Cancer cell growth inhibitory activity of model trienes **3a** and **3b** in vitro (GI_{50} values in μg/mL).

	Pancreas-a BXPC-3	Neuroblast SK-N-SH	Thyroid ca SW 1736	Lung-NSC NCI-H460	Pharynx-sq FADU	Prostate DU-145
3a	0.25	0.31	0.70	0.26	0.27	0.32
3b	3.2	2.2	5.8	6.6	5.0	> 10

Acknowledgments. Financial support was provided by the National Institutes of Health (National Cancer Institute, grant CA-70329), SmithKline Beecham, Dupont Merck Pharmaceutical Co., and Zeneca Inc.

REFERENCES AND NOTES

1. (a) Pettit, G. R. *Pure & Appl. Chem.* **1994**, *66*, 2271. (b) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R. Schmidt, J. M.; Hooper, J. N. A. *J. Org. Chem.* **1993**, *58*, 1302. (c) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L. Boyd, M. R. *J. Chem. Soc., Chem. Commun.* **1993**, 1166. (d) Bai, R.; Taylor, G. F.; Cichacz, Z. A.; Herald, C. L.; Kepler, J. A.; Pettit, G. R.; Hamel, E. *Biochemistry* **1995**, *34*, 9714.
2. Fusetani, N.; Shinoda, K.; Matsunaga, S. *J. Am. Chem. Soc.* **1993**, *115*, 3977.
3. (a) Kobayashi, M.; Aoki, S.; Sakai, H.; Kawazoe, K.; Kihara, N.; Sasaki, T.; Kitagawa, I. *Tetrahedron Lett.* **1993**, *34*, 2795. (b) Kobayashi, M.; Aoki, S.; Kitagawa, I. *Ibid.* **1994**, *35*, 1243. (c) Kobayashi, M.; Aoki, S.; Gato, K.; Kitagawa, I. *Chem. Pharm. Bull.* **1996**, *44*, 2142.
4. Smith, A. B., III; Zhuang, L.; Brook, C. S.; Boldi, A. M.; McBriar, M. D.; Moser, W. H.; Murase, N.; Verhoest, P. R.; Lin, Q. *Tetrahedron Lett.* **1997**, *38*, 8667.
5. Pornet, J. *Tetrahedron Lett.* **1981**, *22*, 453.
6. Hosokawa, S.; Isobe, M. *Synlett* **1996**, 351.
7. Akiyama, E.; Hirama, M. *Synlett* **1996**, 100.
8. De Lima, C.; Julia, M.; Verpeaux, J.-N. *Synlett* **1992**, 133.
9. The structure assigned to each new compound is in accord with its infrared, 500 MHz ^1H NMR, and 125 MHz ^{13}C NMR spectra, as well as appropriate parent ion identification by high resolution mass spectrometry.
10. Dale, J. A.; Mosher, H. S. *J. Am. Chem. Soc.* **1973**, *95*, 512.
11. (a) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155. (b) Ireland, R. E.; Liu, L. *Ibid.* **1993**, *58*, 2899.